Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Globally there is an urgency to develop effective, low-cost therapeutic interventions for coronavirus disease 2019 (COVID-19). We previously generated the stable and ultrapotent homotrimeric Pittsburgh inhalable Nanobody 21 (PiN-21). Using Syrian hamsters that model moderate to severe COVID-19 disease, we demonstrate the high efficacy of PiN-21 to prevent and treat SARS-CoV-2 infection. Intranasal delivery of PiN-21 at 0.6 mg/kg protects infected animals from weight loss and substantially reduces viral burdens in both lower and upper airways compared to control. Aerosol delivery of PiN-21 facilitates deposition throughout the respiratory tract and dose minimization to 0.2 mg/kg. Inhalation treatment quickly reverses animals’ weight loss post-infection and decreases lung viral titers by 6 logs leading to drastically mitigated lung pathology and prevents viral pneumonia. Combined with the marked stability and low production cost, this novel therapy may provide a convenient and cost-effective option to mitigate the ongoing pandemic.
Article activity feed
-
SciScore for 10.1101/2021.02.23.432569: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: All animal work was performed under the standards of the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH) and according to the Animal Welfare Act guidelines. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable General animal procedures: Syrian hamsters (aged 3-6 months old both male and female) were obtained from the Charles River, MA. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Controls of a validated SARS-CoV-2 antibody-negative, positive human serum, and an uninfected cell, were performed to ensure that virus … SciScore for 10.1101/2021.02.23.432569: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: All animal work was performed under the standards of the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH) and according to the Animal Welfare Act guidelines. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable General animal procedures: Syrian hamsters (aged 3-6 months old both male and female) were obtained from the Charles River, MA. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Controls of a validated SARS-CoV-2 antibody-negative, positive human serum, and an uninfected cell, were performed to ensure that virus neutralization was specific. antibody-negativesuggested: NoneExperimental Models: Cell Lines Sentences Resources The serum–virus mixes (200 μl total) were incubated at 37°C for 1 h, after which they were added dropwise onto confluent Vero E6 cell monolayers in six-well plates. Vero E6suggested: RRID:CVCL_XD71)Software and Algorithms Sentences Resources Graphs were generated using GraphPad Prism, version 9. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)An unstained Syrian hamster lung section was used to create an autofluorescence signature that was subsequently removed from images using InForm software version 2.4.8 (Akoya Biosciences). InFormsuggested: (inForm, RRID:SCR_019155)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
